Compare · HHLA vs ILMN
HHLA vs ILMN
Side-by-side comparison of HH&L Acquisition Co. (HHLA) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HHLA and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $23.91B, about 47.7x HHLA ($500.9M).
- ILMN has hit the wire 22 times in the past 4 weeks while HHLA has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for HHLA).
- Company
- HH&L Acquisition Co.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $500.9M
- $23.91B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 0
- 22
- Recent ratings
- 0
- 25
HH&L Acquisition Co.
HH&L Acquisition Co. is a blank check company. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest HHLA
- SEC Form 25-NSE filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- HH&L Acquisition Co. Shares Halted Under Code News Pending
- HH&L Acquisition Co Decides That It Will Redeem All Of Its Outstanding Ordinary Shares That Were Included In Units Issued In Its IPO; Per-Share Redemption Price For Public Shares Will Be About $10.79, Before Payment Of Taxes And Dissolution Expenses
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits